These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
241 related items for PubMed ID: 24718774
1. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Donders G, Neven P, Moegele M, Lintermans A, Bellen G, Prasauskas V, Grob P, Ortmann O, Buchholz S. Breast Cancer Res Treat; 2014 Jun; 145(2):371-9. PubMed ID: 24718774 [Abstract] [Full Text] [Related]
2. Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. Donders G, Bellen G, Neven P, Grob P, Prasauskas V, Buchholz S, Ortmann O. Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):2023-8. PubMed ID: 26223323 [Abstract] [Full Text] [Related]
4. Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. Jaisamrarn U, Triratanachat S, Chaikittisilpa S, Grob P, Prasauskas V, Taechakraichana N. Climacteric; 2013 Jun; 16(3):347-55. PubMed ID: 23347400 [Abstract] [Full Text] [Related]
5. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting. Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, Bermejo-De Las Heras B, Nieto-Magro C. Oncologist; 2020 Dec; 25(12):e1846-1854. PubMed ID: 32459035 [Abstract] [Full Text] [Related]
7. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. JAMA Oncol; 2017 Mar 01; 3(3):313-319. PubMed ID: 27832260 [Abstract] [Full Text] [Related]
9. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Mueck AO, Ruan X, Prasauskas V, Grob P, Ortmann O. Climacteric; 2018 Apr 01; 21(2):140-147. PubMed ID: 29381086 [Abstract] [Full Text] [Related]
10. [Local administration of low-dose estriol and vital Lactobacillus acidophilus in postmenopause]. Kanne B, Jenny J. Gynakol Rundsch; 1991 Apr 01; 31(1):7-13. PubMed ID: 1906830 [Abstract] [Full Text] [Related]
11. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Pfeiler G, Glatz C, Königsberg R, Geisendorfer T, Fink-Retter A, Kubista E, Singer CF, Seifert M. Climacteric; 2011 Jun 01; 14(3):339-44. PubMed ID: 21226657 [Abstract] [Full Text] [Related]
12. Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Sulaica E, Han T, Wang W, Bhat R, Trivedi MV, Niravath P. Breast Cancer Res Treat; 2016 Jun 01; 157(2):203-210. PubMed ID: 27178335 [Abstract] [Full Text] [Related]
13. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients. Kunovac Kallak T, Baumgart J, Stavreus Evers A, Sundström Poromaa I, Moby L, Kask K, Norjavaara E, Kushnir MM, Bergquist J, Nilsson K. Climacteric; 2012 Oct 01; 15(5):473-80. PubMed ID: 22324859 [Abstract] [Full Text] [Related]
14. Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. Delgado JL, Estevez J, Radicioni M, Loprete L, Moscoso Del Prado J, Nieto Magro C. Climacteric; 2016 Apr 01; 19(2):172-80. PubMed ID: 26786399 [Abstract] [Full Text] [Related]
15. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, Ravarino N, Ponzone R, Sismondi P. Gynecol Endocrinol; 2010 Jun 01; 26(6):404-12. PubMed ID: 20196634 [Abstract] [Full Text] [Related]
16. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. Chollet JA, Carter G, Meyn LA, Mermelstein F, Balk JL. Menopause; 2009 Jun 01; 16(5):978-83. PubMed ID: 19390463 [Abstract] [Full Text] [Related]
17. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors. Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ. J Clin Endocrinol Metab; 2018 Nov 01; 103(11):4146-4154. PubMed ID: 30239842 [Abstract] [Full Text] [Related]
18. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Dugal R, Hesla K, Sørdal T, Aase KH, Lilleeidet O, Wickstrøm E. Acta Obstet Gynecol Scand; 2000 Apr 01; 79(4):293-7. PubMed ID: 10746845 [Abstract] [Full Text] [Related]
19. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H. Oncologist; 2011 Apr 01; 16(4):424-31. PubMed ID: 21385795 [Abstract] [Full Text] [Related]
20. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Cano A, Estévez J, Usandizaga R, Gallo JL, Guinot M, Delgado JL, Castellanos E, Moral E, Nieto C, del Prado JM, Ferrer J. Menopause; 2012 Oct 01; 19(10):1130-9. PubMed ID: 22914208 [Abstract] [Full Text] [Related] Page: [Next] [New Search]